@fotiosbarkas.bsky.social
Assistant Professor of Internal Medicine @ University of Ioannina | Research Fellow @ ICCP & ICTU, Faculty of Medicine, Imperial College London, UK | EAS Young Fellow & SoMe Ambassador | FN SCOPE | Lipidology, Obesity Expert
💡 Why it matters
Risk- and benefit-based DSS tools may still add value - especially in #primarycare, where guideline gaps persist and #EHR-integrated solutions could scale impact.
🔍 What did we find?
• No significant difference vs standard of care
• But a favorable signal towards greater and earlier use of combination LLT (61.6% vs 50.6%) and therefore LDL-C target attainment
• High usability & feasibility in routine practice
🔔 In case you missed it, check our recent publication from the #ZODIAC trial!
📊 1,139 ACS patients | 42 hospitals | UK, Italy & Spain
We tested whether a personalized clinical hashtag#DSS estimating #CVD risk and benefit from different #LLT strategies could improve lipid management after ACS.
Webinar | 🗓️ 20/10/25, 18:00 (Zoom)
Από τις Οδηγίες 2019 ➜ 2025:
Τι αλλάζει στη διαχείριση των δυσλιπιδαιμιών;
🎙️ Ε. Λυμπερόπουλος | Χ. Μηλιώνης
👨⚕️ Προεδρείο: Φ. Μπάρκας
🔗 Εγγραφή: bit.ly/has-lipids202
#Lipids #Cardiology #HAS #EAS #Webinar
Evidence-based, scalable & practical — a path to change the #ASCVD trajectory.
Keypoints: ✅ Start early with potent oral combination therapy in high-risk or #ASCVD patients. ✅ Escalate to triple therapy (PCSK9-targeted agents or bempedoic acid) if not at target. ✅ Follow-up, adherence & optimization are key.
👉 doi.org/10.1093/eurheartj/eh...
Let’s fight back years of inertia in #lipid management by shifting from reactive “treat-and-wait” care to a proactive “Fire-and-Forget” approach — ensuring early, potent & sustained #LDL-C reduction!
Delighted to share our new paper published in the European Heart Journal.
🚀 Big win for #ASCVD Prevention!
The VESALIUS-CV Phase 3 trial fullfilled its primary endpoints: #evolocumab significantly reduced CVD events in high-risk patients without prior AMI or stroke. 💥💓
This is a major leap forward for primary prevention!
zurl.co/SPJSp
📢 Υποβολή περιλήψεων – HAS 2025!
📝 Προθεσμία: 15/10/2025 | 📩 Αποδοχή: 1/11/2025
👉 zurl.co/wkyt1
#HAS2025 #Atherosclerosis #CardioResearch
👏 Well done Nikolaos - Gavriil Kolios, who is one of my PhD Students, and the rest of the team George Ntaios H Milionis #Stroke #ACS #LipidLowering #cholesterol
👌 We know what to do after acute #coronary events
🤔 But what about stroke 🧠, the leading cause of #disability worldwide?
🧐 What’s the evidence 📚, which drugs 💊, and how low to go 📉?
Enjoy 👇 www.thieme-connect.com/products/ejo...
#EASYOUNGFELLOWS #EAS
#SGLT2i #Atherosclerosis #Diabetes #CVPrevention
🚨 Just out in the American Journal of Preventive Cardiology!
Our latest review on the atheroprotective power of #SGLT2 inhibitors 💥
From 🧠 #stroke to #CAD & #PAD — SGLT2i are changing the game in #CVD prevention!
Read it here!
doi.org/10.1016/j.aj...
📖 Read the full paper here:
🔗 www.jacc.org/doi/10.1016/...
👏 Huge credit to all INTERASPIRE Investigators for this global contribution to cardiovascular prevention!
#LipoproteinA #Lp_a #CVDPrevention #CardioTwitter #Lipidology #JACC #GlobalHealth
4️⃣ Most patients with high Lp(a) also had poorly controlled traditional risk factors.
📈 In regions lacking access to novel therapies, risk factor management must be improved several fold to offset Lp(a)-related residual risk.
3️⃣ Traditional lipids don’t predict Lp(a).
LDL-C, non–HDL-C, and ApoB did not correlate with Lp(a) across most of its range.
✅ Bottom line: Measure Lp(a) directly—don’t rely on traditional lipids.
2️⃣ Eligibility for emerging Lp(a)-lowering therapies:
▪️ 6.2% at ≥200 nmol/L
▪️ 13.0% at ≥150 nmol/L
⚠️ Marked variation across WHO regions and even between countries within the same region.
1️⃣ Median Lp(a): 32 nmol/L
👉 82.4% of patients were below the 125 nmol/L threshold typically linked to increased ASCVD risk.
🧠 Suggests that Lp(a)’s contribution to CHD may be more complex than previously assumed.
🚨 Recently in @jaccjournals.bsky.social Key findings from the INTERASPIRE study on Lp(a) in 3,928 CHD patients across 13 countries 🌍
A 🧵 on what we found & what it means for future Lp(a)-lowering therapies:
🔜 See you next year—and don’t forget:
📍 December 2025 in Athens: Panhellenic Congress of HAS Working Groups
📍 May 2026 in Athens: EAS Congress
🎓 And just like that, our Summer School has come to an end!
A heartfelt THANK YOU to all our amazing speakers and the engaged scholars who enriched the sessions with their questions and insights! 🙌
What a truly fruitful and inspiring experience!
#Dyslipidemia #SummerSchool #HAS2025 #EAS #Lipids
🎉 The HAS Summer School has just kicked off!!
🧑🎓Time to dive deep into #lipoprotein metabolism with Prof Alexandros Tselepis and the epidemiology of secondary #dyslipidemias with Prof Demosthenes Panagiotakos!
#HellenicAtherosclerosisSociety #HAS2025
us02web.zoom.us/webinar/regi...
#Lipids #Hypertriglyceridemia #triglycerides #CVD #cardiovasculardisease
🚨 Don’t miss this must-attend webinar!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!
📍See you in Athens this December & at #EASCongress2026 in May!
#atherosclerosis #HAS #CVD #EAS2025 #Cyprus #Greece
🎉 The 1st Pan-Cypriot Atherosclerosis Congress 🇨🇾 concluded with great success!
A flawlessly organized event with high-level scientific content and warm hospitality.
Representing the Hellenic Atherosclerosis Society 🇬🇷, we extend a big thank you to our colleagues in Cyprus!
A deep dive into secondary causes of #dyslipidemia, interactive sessions & the latest in #CardiovascularPrevention in a closed meeting with chosen scholars from #Greece and #Cyprus!💡
#Atherosclerosis #Syros2025 #MedicalEducation #Lipids #SummerSchool #ConferreMedConnect
🚨 Coming up: 18th Summer School of the Hellenic Atherosclerosis Society
🗓 June 6–7, 2025 | 📍Syros, Greece 🇬🇷
